Report Description of the APAC Cardiovascular Devices Market Analysis

Research Scope and Assumption

• The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)


• The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis


• We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses


• All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis


• Inflation has not been accounted for in order to estimate and forecast the market


• Numbers may not add up due to rounding off

Reason to buy the report:

• Facilitate decision-making based on strong current and forecast data for APAC Cardiovascular Devices Market Analysis


• Develop strategies based on the latest regulatory framework


• Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market


• Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the APAC Cardiovascular Devices Market Analysis


• Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders


• To strategically profile key players and comprehensively analyze their market shares and core competencies


• We have technically sound team which do a deep dive research and also provide strategy based consulting analysis

APAC Cardiovascular Devices Market Analysis Executive Summary

The cardiovascular devices is an emerging field in the medical industry and has led to various developments of the products, in the field of cardiology. Many of the market players are developing novel products in order to minimize the burden of cardiovascular diseases such as heart stroke, congenital heart disease, coronary artery disease, cerebrovascular heart disease, heart arrhythmia and rheumatic heart disease. These diseases can be treated using a variety of advanced medical devices such as pacemakers, left-ventricle assist devices and implantable cardioverter defibrillators.

Market Size and Key Findings

The APAC Cardiovascular Devices Market Analysis size stood at around USD 8.85 billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 7% during the forecast period.

The Asia-Pacific Cardiovascular devices market size was valued at $8.85 billion in 2020 and is projected to reach xx million by 2028, registering a CAGR of 7% from 2020 to 2028.



Market Dynamics

Market Growth Drivers Analysis

The growth of the cardiovascular devices market is primarily attributed to the increasing acquisitions and collaboration activities and increasing rate of obesity. The growth of the cardiovascular devices market is primarily attributed to the increasing acquisitions and collaboration activities and increasing rate of obesity. There is a higher increasing risk of developing complications and premature mortality with obese population. Obesity plays a major role in increasing cardiovascular diseases among the population across the region.

Market Restraints

Shortage of skilled workers is likely to pose a negative impact on the market growth.

COVID-19 impact on APAC Cardiovascular Devices Market

The COVID-19 pandemic impacted the production of cardiovascular devices in 2020. Furthermore, the delay of elective procedures due to COVID-19-related measures has adversely affected the cardiovascular medical devices market, especially in 2020. While some cardiovascular procedures are considered urgent, others have been postponed and delayed since the beginning of the global pandemic. Hence, lifestyle changes and medication can be temporarily prescribed instead of cardiovascular procedures for some patients. Another factor negatively impacting the market is the reduction in the diagnosis of cardiovascular diseases due to healthcare resources being reserved for COVID-19 patients. Many medical device companies have experienced losses in their cardiovascular devices business due to the pandemic.

Competitive Landscape

Key Players

The companies which are contributing to the growth of the Asia-Pacific cardiovascular devices market include Abbott Laboratories, Boston Scientific Corp., Edwards Life sciences Corp., Medtronic PLC, Terumo Corp., and Becton, Dickinson and Co. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.

Products in Pipeline

In January 2016, Lepu announced that it was investigating opportunities to sell its pacemakers to the Indian market. Thus, the cardiovascular devices market is anticipated to grow due to increasing acquisitions and collaboration activities in the region.

Notable Recent Deals

• According to the World Health Organization (WHO), particular in South Asia, 97% increase in CVD deaths experienced from 1990 to 2013. In addition, in China, nearly 230 million people out of the countrys 1.3 billion currently suffer from CVDs. In 2015, Japan-based Nipro Corp. acquired Infraredx, a U.S. company that is specialized in building intravascular imaging devices. Moreover, BSP, Ltd., an Israeli device manufacturer, which is engaged in manufacturing heart monitoring equipment, has marketing its products throughout Southeast Asia. Recently, it teamed up with Schiller, a Swiss company, to sell a variety of ECG products to hospitals and healthcare providers in Asia. The products of these companies are used in the diagnosis and monitoring of various heart conditions. Additionally, MicroPort received market approval in Indonesia to launch its Foxtrot balloon catheter, in February 2016.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

CVD policies do exist in some form in all economies studied, however there is substantial room for improvement. Policies on modifiable risk factors exist but the success of translating these into legislation and action, along with measuring impact, remains to be defined. Only one market (Australia) has a comprehensive public health awareness campaign. Clinical practice guidelines for CVD secondary prevention, myocardial infarction and stroke vary substantially across economies. Primary care systems are evolving in many Asian economies, and integration of services is a work in progress.